| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | AN3; MC7; DIPB; HSA249128 |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human TRIM44 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TRIM44抗体的3篇参考文献，内容基于典型研究方向概括：
1. **"TRIM44 promotes tumorigenesis and EMT via activating Wnt/β-catenin signaling in pancreatic cancer"**
- **作者**: Li Y, et al.
- **摘要**: 该研究通过免疫组化(IHC)和Western blot验证TRIM44在胰腺癌中高表达，并发现其通过激活Wnt/β-catenin信号通路促进肿瘤侵袭和上皮-间质转化(EMT)。TRIM44抗体被用于检测临床样本中的蛋白表达水平，提示其作为潜在治疗靶点。
2. **"High expression of TRIM44 correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma"**
- **作者**: Wang X, et al.
- **摘要**: 研究利用TRIM44抗体对肝癌组织进行免疫组化分析，发现TRIM44高表达与患者预后不良相关。机制上，TRIM44可能通过调节PD-L1表达影响肿瘤免疫微环境，为肝癌免疫治疗提供新方向。
3. **"TRIM44 interacts with and stabilizes HER2 to drive breast cancer progression and chemoresistance"**
- **作者**: Zhang H, et al.
- **摘要**: 研究通过共免疫沉淀(Co-IP)和免疫荧光证实TRIM44与HER2蛋白结合，并增强其稳定性，导致乳腺癌化疗耐药。TRIM44抗体用于检测蛋白相互作用及表达水平，提示靶向TRIM44可能改善HER2阳性乳腺癌疗效。
**注**：以上文献名为模拟概括，实际引用需以具体论文标题和内容为准。建议通过PubMed或Google Scholar搜索关键词“TRIM44 antibody”、“TRIM44 cancer”获取原文。
The TRIM44 antibody is a research tool designed to detect and study the TRIM44 protein, a member of the tripartite motif (TRIM) family. TRIM proteins are characterized by conserved RING, B-box, and coiled-coil domains, and many function as E3 ubiquitin ligases involved in protein degradation, immune regulation, and cancer progression. TRIM44. however, lacks the canonical RING domain, suggesting distinct mechanisms compared to other TRIM members. It has been implicated in tumorigenesis, with studies linking its overexpression to aggressive phenotypes in cancers such as hepatocellular carcinoma, gastric cancer, and breast cancer. TRIM44 is thought to promote oncogenesis by modulating key signaling pathways, including mTOR and Hippo, thereby enhancing cell proliferation, metastasis, and chemoresistance.
Antibodies targeting TRIM44 are widely used in experimental techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and clinical relevance. Research using these antibodies has revealed that high TRIM44 levels correlate with poor prognosis in multiple cancers, underscoring its potential as a diagnostic or prognostic biomarker. Additionally, TRIM44 antibodies aid in exploring its functional roles in vitro and in vivo, such as its interaction with ubiquitination pathways or tumor microenvironment regulation. Despite progress, the precise molecular mechanisms of TRIM44 remain under investigation, and its therapeutic potential as a drug target is an active area of study. Commercial TRIM44 antibodies vary in specificity and validation, requiring careful selection for experimental accuracy.
×
